Skip to main content

Table 2 Characteristics of cohort of biopsy-proven NASH patients

From: Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption

  Steatosis 0–1 Steatosis 2–3 p (T-test)
n 40 36 /
M/F 22/18 24/12 NS (Chi-Squared)
Age (years) 58.5 ± 1.7 53.6 ± 1.9 NS (0.06)
BMI (kg/m2) 31.6 ± 0.6 32.6 ± 0.9 NS
Metabolic assessment
 Glucose (mmol/L) 6.2 ± 0.3 7.0 ± 0.4 NS (0.1)
 Insulin (pmol/L) 109.6 ± 11.0 130.7 ± 12.6 NS
 HOMA2-IR 2.1 ± 0.2 2.5 ± 0.2 NS
 TAGs (mmol/L) 1.8 ± 0.2 1.9 ± 0.3 NS
 Total cholesterol (mmol/L) 4.3 ± 0.2 4.3 ± 0.1 NS
 LDL cholesterol (mmol/L) 2.6 ± 0.2 2.6 ± 0.1 NS
 HDL cholesterol (mmol/L) 1.0 ± 0.1 1.0 ± 0.03 NS
Liver function tests
 AST (U/L) 41.5 ± 3.8 46.7 ± 3.9 NS
 ALT (U/L) 53.02 ± 3.9 72.9 ± 6.3 < 0.01*
 ALP (U/L) 118.4 ± 9.5 104.1 ± 6.7 NS
Histology
NASH activity score 2.8 ± 0.2 4.8 ± 0.2 < 0.01*
 - Steatosis 0.8 ± 0.02 2.3 ± 0.1 < 0.01*
 - Ballooning 0.7 ± 0.1 1.0 ± 0.1 0.03*
 - Inflammation 1.4 ± 0.1 1.5 ± 0.1 NS
Fibrosis 1.5 ± 0.2 1.8 ± 0.2 NS
  1. * p < 0.05